Cargando…
Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease
Patients with transfusion‐dependent sickle cell disease (SCD) are at risk of iron overload and its complications. Iron overload is a significant risk factor for chronic liver disease in patients who are dependent on hemodialysis secondary to end-stage renal disease (ESRD). Deferasirox is being incre...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107315/ https://www.ncbi.nlm.nih.gov/pubmed/35582552 http://dx.doi.org/10.7759/cureus.24146 |